ATE160585T1 - Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie - Google Patents

Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie

Info

Publication number
ATE160585T1
ATE160585T1 AT93921471T AT93921471T ATE160585T1 AT E160585 T1 ATE160585 T1 AT E160585T1 AT 93921471 T AT93921471 T AT 93921471T AT 93921471 T AT93921471 T AT 93921471T AT E160585 T1 ATE160585 T1 AT E160585T1
Authority
AT
Austria
Prior art keywords
met
hgf
antibody
substance
hepatocyt
Prior art date
Application number
AT93921471T
Other languages
English (en)
Inventor
Donna L Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
Woude George F Vande
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE160585T1 publication Critical patent/ATE160585T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93921471T 1992-09-18 1993-09-15 Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie ATE160585T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18

Publications (1)

Publication Number Publication Date
ATE160585T1 true ATE160585T1 (de) 1997-12-15

Family

ID=25483898

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93921471T ATE160585T1 (de) 1992-09-18 1993-09-15 Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
AT97201105T ATE368738T1 (de) 1992-09-18 1993-09-15 Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97201105T ATE368738T1 (de) 1992-09-18 1993-09-15 Medizinische verwendung eines antikörpers oder eines antikörperfragments gegen die extrazelluläre domäne von met zur prevention von metastasen

Country Status (10)

Country Link
EP (2) EP0662130B1 (de)
JP (2) JP3553936B2 (de)
AT (2) ATE160585T1 (de)
AU (1) AU675968B2 (de)
CA (1) CA2144856A1 (de)
DE (2) DE69315440T2 (de)
DK (1) DK0662130T3 (de)
ES (1) ES2112997T3 (de)
GR (1) GR3026165T3 (de)
WO (1) WO1994006909A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
EP0661993B1 (de) * 1992-09-16 1997-05-07 Genentech, Inc. Schutz gegen leberschäden mit hgf
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
CA2270867A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
WO2000025727A2 (en) * 1998-11-04 2000-05-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
US7459536B1 (en) 1999-11-09 2008-12-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HGF-SF monoclonal antibody combinations
AU7785401A (en) * 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
CA2532027C (en) 2003-07-18 2016-06-14 Amgen Inc. Specific binding agents to hepatocyte growth factor
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7476724B2 (en) 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
US7737115B2 (en) 2005-04-15 2010-06-15 Genetech, Inc. HGF beta chain variants
WO2007119447A1 (ja) * 2006-03-20 2007-10-25 Seikagaku Corporation 関節リウマチの処置剤
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
KR102059663B1 (ko) 2010-03-10 2019-12-26 젠맵 에이/에스 Ｃ―ｍｅｔ에 대한 모노클로날 항체
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
CA2832113C (en) 2011-04-02 2020-07-21 Washington State University Research Foundation Hepatocyte growth factor mimics as therapeutic agents
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10450376B2 (en) 2014-09-16 2019-10-22 Symphogen A/S Anti-MET antibodies and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648273A (en) * 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
ATE256736T1 (de) * 1990-09-14 2004-01-15 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JPH07508420A (ja) * 1992-05-18 1995-09-21 ジェネンテク，インコーポレイテッド 肝細胞成長因子変異体

Also Published As

Publication number Publication date
AU675968B2 (en) 1997-02-27
EP0662130A1 (de) 1995-07-12
DK0662130T3 (da) 1998-08-10
ATE368738T1 (de) 2007-08-15
GR3026165T3 (en) 1998-05-29
CA2144856A1 (en) 1994-03-31
AU4855593A (en) 1994-04-12
DE69315440D1 (de) 1998-01-08
WO1994006909A3 (en) 1994-05-26
JP3553936B2 (ja) 2004-08-11
DE69315440T2 (de) 1998-07-09
EP0805203A1 (de) 1997-11-05
JPH08504093A (ja) 1996-05-07
WO1994006909A2 (en) 1994-03-31
DE69334159D1 (de) 2007-09-13
JP2004002440A (ja) 2004-01-08
ES2112997T3 (es) 1998-04-16
EP0662130B1 (de) 1997-11-26
EP0805203B1 (de) 2007-08-01

Similar Documents

Publication Publication Date Title
ATE160585T1 (de) Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
ATE236271T1 (de) Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
DE69736197D1 (de) Antikoagulierende humanisierte Antikörper gegen Faktor IX, zur Verwendung in der Behandlung von Thrombose
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
ATE339450T1 (de) Verfahren zur behandlung von entzündungen
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
ATE203421T1 (de) Keime von kobalt-palladium zur thermischen behandlung von tumoren
BG101024A (bg) Моноклонално антитяло срещу сd44v6
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69328726D1 (de) Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
ATE111519T1 (de) Familie von modifizierten antikörpern mit hoher affinität zur behandlung von krebs.
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE69314234D1 (de) Konservierte Polysiloxanemulsion zur Behandlung von Geweben
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69607034D1 (de) Pcna bindende substanz
DE59401744D1 (de) Verfahren zur Herstellung von Difluormethoxy- und Difluormethylthioarenen
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE59907958D1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee